These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36542670)

  • 1. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
    Bell CF; Huang SP; Cyhaniuk A; Averell CM
    Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM
    BMC Health Serv Res; 2024 May; 24(1):691. PubMed ID: 38822336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015.
    Hammond ER; Desta B; Near AM; Wang X; Jiang M
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34556546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
    Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus flare and recurrent lupus nephritis following kidney transplantation in patients with lupus nephritis.
    Kim YE; Kim JM; Ahn SM; Oh JS; Kim YG; Lee CK; Yoo B; Shin S; Hong S
    Int J Rheum Dis; 2024 Sep; 27(9):e15349. PubMed ID: 39306750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
    He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
    Value Health Reg Issues; 2024 Sep; 43():101001. PubMed ID: 38850589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
    Wu SS; Perry A; Tkacz J; Bryant G
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
    [No Abstract]   [Full Text] [Related]  

  • 12. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
    Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
    Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
    Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
    J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid.
    Kan HJ; Song X; Johnson BH; Bechtel B; O'Sullivan D; Molta CT
    Biomed Res Int; 2013; 2013():808391. PubMed ID: 23484162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
    Lokhandwala T; Yue B; Coutinho AD; Bell CF
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33558436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany.
    Ding B; Pignot M; Garal-Pantaler E; Villinger B; Schefzyk S; Desta B; Stirnadel-Farrant HA; Schwarting A
    Rheumatol Ther; 2024 Apr; 11(2):285-299. PubMed ID: 38252212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validating claims-based algorithms for a systemic lupus erythematosus diagnosis in Medicare data for informed use of the Lupus Index: a tool for geospatial research.
    Feldman C; Curtis JR; Oates JC; Yazdany J; Izmirly P
    Lupus Sci Med; 2024 Oct; 11(2):. PubMed ID: 39401954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States.
    Dall'Era M; Kalunian K; Eaddy M; Ogbonnaya A; Farrelly E; Turowski E; Birardi V; Solomons N; Randhawa S; Mina-Osorio P
    J Manag Care Spec Pharm; 2023 Jan; 29(1):36-45. PubMed ID: 36190835
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.